CLINICAL TRIALS PROFILE FOR VILTOLARSEN
✉ Email this page to a colleague
All Clinical Trials for viltolarsen
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04060199 ↗ | Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) | Recruiting | Nippon Shinyaku Co., Ltd. | Phase 3 | 2020-04-14 | The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. |
| NCT04060199 ↗ | Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) | Recruiting | NS Pharma, Inc. | Phase 3 | 2020-04-14 | The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. |
| NCT04687020 ↗ | Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) | Recruiting | NS Pharma, Inc. | Phase 4 | 2021-06-10 | The VILT-502 study is Non-interventional Study(United States)/Low-intervention Clinical Trial (Canada) of Viltolarsen administered intravenously once weekly for 10 years to boys with DMD who complete the NS-065/NCNP-01-202 study. |
| NCT04768062 ↗ | Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) | Recruiting | Nippon Shinyaku Co., Ltd. | Phase 3 | 2021-04-13 | This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301. |
| NCT04768062 ↗ | Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) | Recruiting | NS Pharma, Inc. | Phase 3 | 2021-04-13 | This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301. |
| NCT04956289 ↗ | Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD | Recruiting | Nippon Shinyaku Co., Ltd. | Phase 2 | 2021-07-01 | This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years. |
| NCT04956289 ↗ | Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD | Recruiting | NS Pharma, Inc. | Phase 2 | 2021-07-01 | This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for viltolarsen
Condition Name
Clinical Trial Locations for viltolarsen
Trials by Country
Clinical Trial Progress for viltolarsen
Clinical Trial Phase
Clinical Trial Sponsors for viltolarsen
Sponsor Name
